Antibody-Mediated Therapy and Other Emerging Therapies in Cancer Treatment

Topic Information

Dear Colleagues,

Recent advances in antibody-mediated therapy have significantly improved its therapeutic efficacy in many types of cancer. Antibody-mediated therapy includes the following:

1. Monoclonal antibodies against specific targets associated with cancer cell survival, progression, metastasis, and drug resistance;
2. Monoclonal antibodies against specific targets that are relatively highly expressed in cancer cells or are cancer-specific, regardless of cancer cell survival progression, metastasis, or drug resistance;
3. Monoclonal antibodies against specific targets in cancer cells or normal cells that modulate the tumor microenvironment, especially immune systems;
4. Antibody–drug conjugates (ADCs) are complex molecules consisting of antibodies conjugated to biologically active cancer cell-killing substances.

These antibody-mediated therapies have been widely used as combination therapies due to their synergistic effects with cytotoxic anticancer drugs. Eventually, ADCs, complex molecules consisting of antibodies and cytotoxic substances, were developed to improve treatment outcomes. However, the side effects of ADCs are very serious, requiring careful monitoring during treatment. Therefore, this Topic was prepared to deeply examine the efficacy, related mechanisms, and toxicities of the latest antibody-related therapies or other novel therapies for each cancer.

Scope of the Topic

1. Monoclonal antibodies as monotherapy, as antibody–drug conjugates (ADCs), or in combination with other drugs in cancer treatment:
2. Efficacy, mechanism of action, and treatment guidelines;
3. Predictive/prognostic biomarkers;
4. Toxicity and management.
5. Other emerging therapies in cancer treatment (CAR-T cell therapy, NK or other cell therapies, oncolytic virus therapy, cancer vaccines, targeted therapy, etc.). 

Dr. Won Sup Lee
Prof. Dr. Yaewon Yang
Prof. Dr. Seil Go
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Cancers cancers	4.4	8.8	2009	17.4 Days	CHF 2900	Submit
Current Issues in Molecular Biology cimb	3.0	3.7	1999	15.8 Days	CHF 2200	Submit
Current Oncology curroncol	3.4	4.9	1994	19.8 Days	CHF 2200	Submit
Scientia Pharmaceutica scipharm	2.5	4.6	1930	26.1 Days	CHF 1000	Submit
Antibodies antibodies	2.7	4.5	2012	22.8 Days	CHF 1800	Submit
International Journal of Molecular Sciences ijms	4.9	9.0	2000	16.8 Days	CHF 2900	Submit
International Journal of Translational Medicine ijtm	-	2.2	2021	24.2 Days	CHF 1000	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers